Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Лекарственно-индуцированное удлинение интервала QT на фоне применения противоопухолевых препаратов
Лекарственно-индуцированное удлинение интервала QT на фоне применения противоопухолевых препаратов
Остроумова О.Д., Кочетков А.И., Дё В.А. Лекарственно-индуцированное удлинение интервала QT на фоне применения противоопухолевых препаратов. Consilium Medicum. 2022;24(6):391–398.
DOI: 10.26442/20751753.2022.6.201542
DOI: 10.26442/20751753.2022.6.201542
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Противоопухолевые препараты могут вызывать лекарственно-индуцированное удлинение интервала QT. В свою очередь, удлинение интервала QT является признанным фактором риска и независимым предиктором развития жизнеугрожающих желудочковых аритмий (прежде всего – полиморфной желудочковой тахикардии/Torsades de Pointes) и внезапной сердечной смерти у лиц как с наличием структурной патологии сердца, так и с ее отсутствием. Практикующие врачи должны постоянно оценивать отношение польза/риск при начале, а также продолжении выбранной терапии. Особое внимание необходимо обратить на пациентов с факторами риска, такими как наличие сопутствующих заболеваний, прием препаратов, ассоциированных с удлинением QT-интервала, дегидратация и электролитные нарушения и др. Несмотря на очевидный рост осведомленности пациентов и медицинского персонала, многие исследователи высказывают предположение о недостаточной степени информированности об истинной распространенности рассматриваемых нежелательных реакций, которая на самом деле превышает имеющиеся в настоящее время данные по меньшей мере в 10 раз. В данной статье рассматриваются противоопухолевые препараты, которые могут быть ассоциированы с удлинением интервала QT, а также особенности тактики ведения пациентов с лекарственно- индуцированным удлинением интервала QT.
Ключевые слова: лекарственно-индуцированное заболевание, удлинение интервала QT, полиморфная желудочковая тахикардия, рак, онкологические заболевания, противоопухолевая терапия
Keywords: drug-induced disease, QT interval prolongation, torsade de pointes, cancer, anticancer drug
Ключевые слова: лекарственно-индуцированное заболевание, удлинение интервала QT, полиморфная желудочковая тахикардия, рак, онкологические заболевания, противоопухолевая терапия
________________________________________________
Keywords: drug-induced disease, QT interval prolongation, torsade de pointes, cancer, anticancer drug
Полный текст
Список литературы
1. Цибулькин Н.А. Синдром удлиненного интервала QT – основные клинико-патофизиологические аспекты. Практическая медицина. 2012;5(60):98-103 [Cibulkin NA. Long QT syndrome – main clinical and pathophysiological aspects. Prakticheskaja medicina. 2012;5(60):98-103 (in Russian)].
2. Haddad PM, Anderson IM. Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death. Drugs. 2002;62(11):1649-71. DOI:10.2165/00003495-200262110-00006
3. Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации МЗ РФ. 2020. Режим доступа: https://mz19.ru/upload/iblock/dea/ZHeludochkovye-narusheniya-ritma.-ZHeludochkovye-takhikardii-2020.... Ссылка активна на: 29.12.2021 [Ventricular arrhythmias. Ventricular tachycardia and sudden cardiac death. Clinical recommendations of the Ministry of Health of the Russian Federation. 2020. Available at: https://mz19.ru/upload/iblock/dea/ZHeludochkovye-narusheniya-ritma.-ZHeludochkovye-takhikardii-2020..... Accessed 29.12.2021 (in Russian)].
4. Головина Г.А., Зафираки В.К., Космачева Е.В. Медикаментозно-индуцированный синдром удлиненного интервала QT. Вестник аритмологии. 2020;27(3):42-52 [Golovina GA, Zafiraki VK, Kosmacheva EV. Drug-induced long QT syndrome. Vestnik aritmologii. 2020;27(3):42-52 (in Russian)].
5. Aktürk G, Kalkan Ş. Drug-Induced QT Interval Prolongation: Mechanisms, Risk Factors, Genetics and Clinical Management. J Basic Clin Health Sci. 2019;3(5):193-8. DOI:10.30621/jbachs.2019.712
6. Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf. 2012;3(5):241-53. DOI:10.1177/2042098612454283
7. Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938-45. DOI:10.1016/j.jacc.2014.06.1167
8. Sarapa N, Huang M, Varterasian M, et al. Risk management and eligibility critieria for QT assessment in patients with advanced cancer. J Clin Oncol. 2005;23(16; Suppl.):3047.
9. Yusuf SW, Razeghi P, Yeh ETH. The Diagnosis and Management of Cardiovascular Disease in Cancer Patients. Curr Probl Cardiol. 2008;33(4):163-96. DOI:10.1016/j.cpcardiol.2008.01.002
10. Остроумова О.Д., Голобородова И.В. Влияние отдельных групп лекарственных препаратов на риск удлинения интервала QTс. Consilium Medicum. 2019;21(10):95-106 [Ostroumova OD, Goloborodova IV. The influence of certain groups of drugs on the QTc interval prolongation. Consilium Medicum. 2019;21(10):95-106 (in Russian)]. DOI:10.26442/20751753.2019.10.190447
11. Остроумова О.Д., Голобородова И.В. Лекарственно-индуцированное удлинение интервала QT: распространенность, факторы риска, лечение и профилактика. Consilium Medicum. 2019;21(5):62-7 [Ostroumova OD, Goloborodova IV. Drug-induced prolongation of the QT interval: prevalence, risk factors, treatment and prevention. Consilium Medicum. 2019;21(5):62-7 (in Russian)]. DOI:10.26442/20751753.2019.5.190415
12. Woosley RL, Heise CW, Gallo T. CredibleMeds. Available at: https://crediblemeds.org/ Accessed: 29.12.2021.
13. Porta-Sánchez A, Gilbert C, Spears D, et al. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J Am Heart Assoc. 2017;6(12):007724. DOI:10.1161/JAHA.117.007724
14. Roden DM. A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. Cardiovasc Res. 2019;115(5):895-903. DOI:10.1093/cvr/cvz013
15. Cohen-Rabbie S, Berges AC, Rekić D, et al. QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small-Molecule New Drug Applications Approved During 2011–2019. J Clin Pharmacol. 2021;61(8):1106-17. DOI:10.1002/jcph.1844
16. Lazzerini PE, Bertolozzi I, Acampa M, et al. Androgen Deprivation Therapy for Prostatic Cancer in Patients With Torsades de Pointes. Front Pharmacol. 2020;11:684. DOI:10.3389/fphar.2020.00684
17. Abu Rmilah AA, Lin G, Begna KH, et al. Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. Int J Cancer. 2020;147(11):3160-7. DOI:10.1002/ijc.33119
18. Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol. 2018;36(3):231-7. DOI:10.1200/JCO.2017.74.7162
19. Larkin J, Del Vecchio M, Ascierto PA, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15(4):436-44. DOI:10.1016/S1470-2045(14)70051-8
20. Duan J, Tao J, Zhai M, et al. Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives. Oncotarget. 2018;9(39):25738-49. DOI:10.18632/oncotarget.25008
21. Dréno B, Ribas A, Larkin J, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol. 2017;28(5):1137-44. DOI:10.1093/annonc/mdx040
22. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689-99. DOI:10.1056/NEJMoa1411817
23. Schiefer M, Hendriks LEL, Dinh T, et al. Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring. Eur J Cancer. 2018;91:92-8. DOI:10.1016/j.ejca.2017.12.011
24. Hortobagyi GN. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Breast Cancer Res. 2018;20(1):123. DOI:10.1186/s13058-018-1050-7
25. Khozin S, Blumenthal GM, Zhang L, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res. 2015;21(11):2436-9. DOI:10.1158/1078-0432.CCR-14-3157
26. Wang H, Cao Q, Dudek AZ. Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res. 2012;32(3):1027-31.
27. Lenihan DJ, Kowey PR. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist. 2013;18:900-8.
DOI:10.1634/theoncologist.2012-0466
28. Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol. 2003;21:3609-15. DOI:10.1200/JCO.2003.10.009
29. Wacker A, Lersch C, Scherpinski U, et al. High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients. Oncology. 2003;65(2):108-12. DOI:10.1159/000072334
30. Koca D, Salman T, Unek IT, et al. Clinical and electrocardiography changes in patients treated with capecitabine. Chemotherapy. 2011;57(5):381-7. DOI:10.1159/000331645
31. Kuittinen T, Jantunen E, Vanninen E, et al. Late potentials and QT dispersion after high-dose chemotherapy in patients with non-Hodgkin lymphoma. Clin Physiol Funct Imaging. 2010;30(3):175-80. DOI:10.1111/j.1475-097X.2009.00920.x
32. Hancox JC, Caves RE, Choisy SC, et al. QT interval prolongation and torsades de pointes with oxaliplatin. Ther Adv Drug Saf. 2016;7(6):261-3. DOI:10.1177/2042098616666081
33. Yin W, Karyagina EV, Lundberg AS, et al. Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. Biopharm Drug Dispos. 2010;31(1):72-81. DOI:10.1002/bdd.690
34. Conte PF, Gennari A. Anthracyclines-paclitaxel combinations in the treatment of breast cancer. Ann Oncol. 1997;8(10):939-43. DOI:10.1023/a:1008208002779
35. Kamineni P, Prakasa K, Hasan SP, et al. Cardiotoxicities of paclitaxel in African Americans. J Natl Med Assoc. 2004;96(7):995.
36. Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991;9(9):1704-12. DOI:10.1200/JCO.1991.9.9.1704
37. Ghatalia P, Je Y, Kaymakcalan MD, et al. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer. 2015;112(2):296-305. DOI:10.1038/bjc.2014.564
38. National Cancer Institute DCTD Division of Cancer Treatment & Diagnosis. Common terminology criteria for adverse events (CTCAE). 2017. Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8..... Accessed 21.12.2021.
39. Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol. 2007;25(22):3362. DOI:10.1200/JCO.2006.09.6925
40. Martin P, Oliver S, Kennedy SJ, et al. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther. 2012;34(1):221-37. DOI:10.1016/j.clinthera.2011.11.011
41. Blackhall FH, O'brien M, Schmid P, et al. A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(8):1285-8. DOI:10.1097/JTO.0b013e3181e3a2d1
42. Liu Y, Liu Y, Fan ZW, et al. Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib. Eur J Clin Pharmacol. 2015;71(5):541-7. DOI:10.1007/s00228-015-1831-1
43. Anon. DailyMed – CAPRELSA – vandetanib tablet. National Library of Medicine. 2017. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e5721cb8-4185-47b9-bbb3-1c587e558a03&.... Accessed 21.12.2021.
44. Tolcher AW, Appleman LJ, Shapiro GI, et al. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2011;67(4):751-64. DOI:10.1007/s00280-010-1372-3
45. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204-12. DOI:10.1200/JCO.2007.15.6331
46. Bergh J, Mariani G, Cardoso F, et al. Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. Breast. 2012;21(4):507-13. DOI:10.1016/j.breast.2012.01.012
47. Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015;17(1):116-21. DOI:10.1093/neuonc/nou148
48. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841-51. DOI:10.1016/S1470-2045(11)70201-7
49. Larson RA, Yin OQ, Hochhaus A, et al. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2012;68(5):723-33. DOI:10.1007/s00228-011-1200-7
50. Abbas R, Chalon S, Leister C, et al. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol. 2013;71(1):123-32. DOI:10.1007/s00280-012-1987-7
51. Abbas R, Hug BA, Leister C, et al. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects. Int J Cancer. 2012;131(3):304-11. DOI:10.1002/ijc.27348
52. Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006;12(12):3762-73. DOI:10.1158/1078-0432.CCR-05-2095
53. Bates SE, Rosing DR, Fojo T, et al. Challenges of evaluating the cardiac effects of anticancer agents. Clin Cancer Res. 2006;12(13):3871-4. DOI:10.1158/1078-0432.CCR-06-1017
54. Lü S, Wang J, Xu X, et al. Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience. Int J Hematol. 2009;89(1):34-8. DOI:10.1007/s12185-008-0218-9
55. Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010;55(2):254-9. DOI:10.1002/pbc.22456
56. Maison-Blanche P, Vermorken JB, Goksel T, et al. A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel. J Cardiovasc Pharmacol. 2013;61(6):495-504. DOI:10.1097/FJC.0b013e31828b73ff
57. Ibrahim MA, Do DV, Sepah YJ, et al. Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate. BMC Pharmacol Toxicol. 2013;14:7. DOI:10.1186/2050-6511-14-7
58. Kloth JS, Pagani A, Verboom MC, et al. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer. 2015;112(6):1011-6. DOI:10.1038/bjc.2015.82
59. Coppola C, Rienzo A, Piscopo G, et al. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs. Cancer Treat Rev. 2018;63:135-43. DOI:10.1016/j.ctrv.2017.11.009
2. Haddad PM, Anderson IM. Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death. Drugs. 2002;62(11):1649-71. DOI:10.2165/00003495-200262110-00006
3. Ventricular arrhythmias. Ventricular tachycardia and sudden cardiac death. Clinical recommendations of the Ministry of Health of the Russian Federation. 2020. Available at: https://mz19.ru/upload/iblock/dea/ZHeludochkovye-narusheniya-ritma.-ZHeludochkovye-takhikardii-2020..... Accessed 29.12.2021 (in Russian).
4. Golovina GA, Zafiraki VK, Kosmacheva EV. Drug-induced long QT syndrome. Vestnik aritmologii. 2020;27(3):42-52 (in Russian).
5. Aktürk G, Kalkan Ş. Drug-Induced QT Interval Prolongation: Mechanisms, Risk Factors, Genetics and Clinical Management. J Basic Clin Health Sci. 2019;3(5):193-8. DOI:10.30621/jbachs.2019.712
6. Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf. 2012;3(5):241-53. DOI:10.1177/2042098612454283
7. Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938-45. DOI:10.1016/j.jacc.2014.06.1167
8. Sarapa N, Huang M, Varterasian M, et al. Risk management and eligibility critieria for QT assessment in patients with advanced cancer. J Clin Oncol. 2005;23(16; Suppl.):3047.
9. Yusuf SW, Razeghi P, Yeh ETH. The Diagnosis and Management of Cardiovascular Disease in Cancer Patients. Curr Probl Cardiol. 2008;33(4):163-96. DOI:10.1016/j.cpcardiol.2008.01.002
10. Ostroumova OD, Goloborodova IV. The influence of certain groups of drugs on the QTc interval prolongation. Consilium Medicum. 2019;21(10):95-106 (in Russian). DOI:10.26442/20751753.2019.10.190447
11. Ostroumova OD, Goloborodova IV. Drug-induced prolongation of the QT interval: prevalence, risk factors, treatment and prevention. Consilium Medicum. 2019;21(5):62-7 (in Russian). DOI:10.26442/20751753.2019.5.190415
12. Woosley RL, Heise CW, Gallo T. CredibleMeds. Available at: https://crediblemeds.org/ Accessed: 29.12.2021.
13. Porta-Sánchez A, Gilbert C, Spears D, et al. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J Am Heart Assoc. 2017;6(12):007724. DOI:10.1161/JAHA.117.007724
14. Roden DM. A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. Cardiovasc Res. 2019;115(5):895-903. DOI:10.1093/cvr/cvz013
15. Cohen-Rabbie S, Berges AC, Rekić D, et al. QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small-Molecule New Drug Applications Approved During 2011–2019. J Clin Pharmacol. 2021;61(8):1106-17. DOI:10.1002/jcph.1844
16. Lazzerini PE, Bertolozzi I, Acampa M, et al. Androgen Deprivation Therapy for Prostatic Cancer in Patients With Torsades de Pointes. Front Pharmacol. 2020;11:684. DOI:10.3389/fphar.2020.00684
17. Abu Rmilah AA, Lin G, Begna KH, et al. Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. Int J Cancer. 2020;147(11):3160-7. DOI:10.1002/ijc.33119
18. Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol. 2018;36(3):231-7. DOI:10.1200/JCO.2017.74.7162
19. Larkin J, Del Vecchio M, Ascierto PA, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15(4):436-44. DOI:10.1016/S1470-2045(14)70051-8
20. Duan J, Tao J, Zhai M, et al. Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives. Oncotarget. 2018;9(39):25738-49. DOI:10.18632/oncotarget.25008
21. Dréno B, Ribas A, Larkin J, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol. 2017;28(5):1137-44. DOI:10.1093/annonc/mdx040
22. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689-99. DOI:10.1056/NEJMoa1411817
23. Schiefer M, Hendriks LEL, Dinh T, et al. Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring. Eur J Cancer. 2018;91:92-8. DOI:10.1016/j.ejca.2017.12.011
24. Hortobagyi GN. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Breast Cancer Res. 2018;20(1):123. DOI:10.1186/s13058-018-1050-7
25. Khozin S, Blumenthal GM, Zhang L, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res. 2015;21(11):2436-9. DOI:10.1158/1078-0432.CCR-14-3157
26. Wang H, Cao Q, Dudek AZ. Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res. 2012;32(3):1027-31.
27. Lenihan DJ, Kowey PR. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist. 2013;18:900-8.
DOI:10.1634/theoncologist.2012-0466
28. Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol. 2003;21:3609-15. DOI:10.1200/JCO.2003.10.009
29. Wacker A, Lersch C, Scherpinski U, et al. High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients. Oncology. 2003;65(2):108-12. DOI:10.1159/000072334
30. Koca D, Salman T, Unek IT, et al. Clinical and electrocardiography changes in patients treated with capecitabine. Chemotherapy. 2011;57(5):381-7. DOI:10.1159/000331645
31. Kuittinen T, Jantunen E, Vanninen E, et al. Late potentials and QT dispersion after high-dose chemotherapy in patients with non-Hodgkin lymphoma. Clin Physiol Funct Imaging. 2010;30(3):175-80. DOI:10.1111/j.1475-097X.2009.00920.x
32. Hancox JC, Caves RE, Choisy SC, et al. QT interval prolongation and torsades de pointes with oxaliplatin. Ther Adv Drug Saf. 2016;7(6):261-3. DOI:10.1177/2042098616666081
33. Yin W, Karyagina EV, Lundberg AS, et al. Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. Biopharm Drug Dispos. 2010;31(1):72-81. DOI:10.1002/bdd.690
34. Conte PF, Gennari A. Anthracyclines-paclitaxel combinations in the treatment of breast cancer. Ann Oncol. 1997;8(10):939-43. DOI:10.1023/a:1008208002779
35. Kamineni P, Prakasa K, Hasan SP, et al. Cardiotoxicities of paclitaxel in African Americans. J Natl Med Assoc. 2004;96(7):995.
36. Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991;9(9):1704-12. DOI:10.1200/JCO.1991.9.9.1704
37. Ghatalia P, Je Y, Kaymakcalan MD, et al. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer. 2015;112(2):296-305. DOI:10.1038/bjc.2014.564
38. National Cancer Institute DCTD Division of Cancer Treatment & Diagnosis. Common terminology criteria for adverse events (CTCAE). 2017. Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8..... Accessed 21.12.2021.
39. Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol. 2007;25(22):3362. DOI:10.1200/JCO.2006.09.6925
40. Martin P, Oliver S, Kennedy SJ, et al. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther. 2012;34(1):221-37. DOI:10.1016/j.clinthera.2011.11.011
41. Blackhall FH, O'brien M, Schmid P, et al. A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(8):1285-8. DOI:10.1097/JTO.0b013e3181e3a2d1
42. Liu Y, Liu Y, Fan ZW, et al. Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib. Eur J Clin Pharmacol. 2015;71(5):541-7. DOI:10.1007/s00228-015-1831-1
43. Anon. DailyMed – CAPRELSA – vandetanib tablet. National Library of Medicine. 2017. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e5721cb8-4185-47b9-bbb3-1c587e558a03&.... Accessed 21.12.2021.
44. Tolcher AW, Appleman LJ, Shapiro GI, et al. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2011;67(4):751-64. DOI:10.1007/s00280-010-1372-3
45. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204-12. DOI:10.1200/JCO.2007.15.6331
46. Bergh J, Mariani G, Cardoso F, et al. Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. Breast. 2012;21(4):507-13. DOI:10.1016/j.breast.2012.01.012
47. Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015;17(1):116-21. DOI:10.1093/neuonc/nou148
48. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841-51. DOI:10.1016/S1470-2045(11)70201-7
49. Larson RA, Yin OQ, Hochhaus A, et al. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2012;68(5):723-33. DOI:10.1007/s00228-011-1200-7
50. Abbas R, Chalon S, Leister C, et al. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol. 2013;71(1):123-32. DOI:10.1007/s00280-012-1987-7
51. Abbas R, Hug BA, Leister C, et al. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects. Int J Cancer. 2012;131(3):304-11. DOI:10.1002/ijc.27348
52. Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006;12(12):3762-73. DOI:10.1158/1078-0432.CCR-05-2095
53. Bates SE, Rosing DR, Fojo T, et al. Challenges of evaluating the cardiac effects of anticancer agents. Clin Cancer Res. 2006;12(13):3871-4. DOI:10.1158/1078-0432.CCR-06-1017
54. Lü S, Wang J, Xu X, et al. Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience. Int J Hematol. 2009;89(1):34-8. DOI:10.1007/s12185-008-0218-9
55. Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010;55(2):254-9. DOI:10.1002/pbc.22456
56. Maison-Blanche P, Vermorken JB, Goksel T, et al. A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel. J Cardiovasc Pharmacol. 2013;61(6):495-504. DOI:10.1097/FJC.0b013e31828b73ff
57. Ibrahim MA, Do DV, Sepah YJ, et al. Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate. BMC Pharmacol Toxicol. 2013;14:7. DOI:10.1186/2050-6511-14-7
58. Kloth JS, Pagani A, Verboom MC, et al. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer. 2015;112(6):1011-6. DOI:10.1038/bjc.2015.82
59. Coppola C, Rienzo A, Piscopo G, et al. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs. Cancer Treat Rev. 2018;63:135-43. DOI:10.1016/j.ctrv.2017.11.009
2. Haddad PM, Anderson IM. Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death. Drugs. 2002;62(11):1649-71. DOI:10.2165/00003495-200262110-00006
3. Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации МЗ РФ. 2020. Режим доступа: https://mz19.ru/upload/iblock/dea/ZHeludochkovye-narusheniya-ritma.-ZHeludochkovye-takhikardii-2020.... Ссылка активна на: 29.12.2021 [Ventricular arrhythmias. Ventricular tachycardia and sudden cardiac death. Clinical recommendations of the Ministry of Health of the Russian Federation. 2020. Available at: https://mz19.ru/upload/iblock/dea/ZHeludochkovye-narusheniya-ritma.-ZHeludochkovye-takhikardii-2020..... Accessed 29.12.2021 (in Russian)].
4. Головина Г.А., Зафираки В.К., Космачева Е.В. Медикаментозно-индуцированный синдром удлиненного интервала QT. Вестник аритмологии. 2020;27(3):42-52 [Golovina GA, Zafiraki VK, Kosmacheva EV. Drug-induced long QT syndrome. Vestnik aritmologii. 2020;27(3):42-52 (in Russian)].
5. Aktürk G, Kalkan Ş. Drug-Induced QT Interval Prolongation: Mechanisms, Risk Factors, Genetics and Clinical Management. J Basic Clin Health Sci. 2019;3(5):193-8. DOI:10.30621/jbachs.2019.712
6. Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf. 2012;3(5):241-53. DOI:10.1177/2042098612454283
7. Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938-45. DOI:10.1016/j.jacc.2014.06.1167
8. Sarapa N, Huang M, Varterasian M, et al. Risk management and eligibility critieria for QT assessment in patients with advanced cancer. J Clin Oncol. 2005;23(16; Suppl.):3047.
9. Yusuf SW, Razeghi P, Yeh ETH. The Diagnosis and Management of Cardiovascular Disease in Cancer Patients. Curr Probl Cardiol. 2008;33(4):163-96. DOI:10.1016/j.cpcardiol.2008.01.002
10. Остроумова О.Д., Голобородова И.В. Влияние отдельных групп лекарственных препаратов на риск удлинения интервала QTс. Consilium Medicum. 2019;21(10):95-106 [Ostroumova OD, Goloborodova IV. The influence of certain groups of drugs on the QTc interval prolongation. Consilium Medicum. 2019;21(10):95-106 (in Russian)]. DOI:10.26442/20751753.2019.10.190447
11. Остроумова О.Д., Голобородова И.В. Лекарственно-индуцированное удлинение интервала QT: распространенность, факторы риска, лечение и профилактика. Consilium Medicum. 2019;21(5):62-7 [Ostroumova OD, Goloborodova IV. Drug-induced prolongation of the QT interval: prevalence, risk factors, treatment and prevention. Consilium Medicum. 2019;21(5):62-7 (in Russian)]. DOI:10.26442/20751753.2019.5.190415
12. Woosley RL, Heise CW, Gallo T. CredibleMeds. Available at: https://crediblemeds.org/ Accessed: 29.12.2021.
13. Porta-Sánchez A, Gilbert C, Spears D, et al. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J Am Heart Assoc. 2017;6(12):007724. DOI:10.1161/JAHA.117.007724
14. Roden DM. A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. Cardiovasc Res. 2019;115(5):895-903. DOI:10.1093/cvr/cvz013
15. Cohen-Rabbie S, Berges AC, Rekić D, et al. QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small-Molecule New Drug Applications Approved During 2011–2019. J Clin Pharmacol. 2021;61(8):1106-17. DOI:10.1002/jcph.1844
16. Lazzerini PE, Bertolozzi I, Acampa M, et al. Androgen Deprivation Therapy for Prostatic Cancer in Patients With Torsades de Pointes. Front Pharmacol. 2020;11:684. DOI:10.3389/fphar.2020.00684
17. Abu Rmilah AA, Lin G, Begna KH, et al. Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. Int J Cancer. 2020;147(11):3160-7. DOI:10.1002/ijc.33119
18. Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol. 2018;36(3):231-7. DOI:10.1200/JCO.2017.74.7162
19. Larkin J, Del Vecchio M, Ascierto PA, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15(4):436-44. DOI:10.1016/S1470-2045(14)70051-8
20. Duan J, Tao J, Zhai M, et al. Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives. Oncotarget. 2018;9(39):25738-49. DOI:10.18632/oncotarget.25008
21. Dréno B, Ribas A, Larkin J, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol. 2017;28(5):1137-44. DOI:10.1093/annonc/mdx040
22. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689-99. DOI:10.1056/NEJMoa1411817
23. Schiefer M, Hendriks LEL, Dinh T, et al. Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring. Eur J Cancer. 2018;91:92-8. DOI:10.1016/j.ejca.2017.12.011
24. Hortobagyi GN. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Breast Cancer Res. 2018;20(1):123. DOI:10.1186/s13058-018-1050-7
25. Khozin S, Blumenthal GM, Zhang L, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res. 2015;21(11):2436-9. DOI:10.1158/1078-0432.CCR-14-3157
26. Wang H, Cao Q, Dudek AZ. Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res. 2012;32(3):1027-31.
27. Lenihan DJ, Kowey PR. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist. 2013;18:900-8.
DOI:10.1634/theoncologist.2012-0466
28. Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol. 2003;21:3609-15. DOI:10.1200/JCO.2003.10.009
29. Wacker A, Lersch C, Scherpinski U, et al. High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients. Oncology. 2003;65(2):108-12. DOI:10.1159/000072334
30. Koca D, Salman T, Unek IT, et al. Clinical and electrocardiography changes in patients treated with capecitabine. Chemotherapy. 2011;57(5):381-7. DOI:10.1159/000331645
31. Kuittinen T, Jantunen E, Vanninen E, et al. Late potentials and QT dispersion after high-dose chemotherapy in patients with non-Hodgkin lymphoma. Clin Physiol Funct Imaging. 2010;30(3):175-80. DOI:10.1111/j.1475-097X.2009.00920.x
32. Hancox JC, Caves RE, Choisy SC, et al. QT interval prolongation and torsades de pointes with oxaliplatin. Ther Adv Drug Saf. 2016;7(6):261-3. DOI:10.1177/2042098616666081
33. Yin W, Karyagina EV, Lundberg AS, et al. Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. Biopharm Drug Dispos. 2010;31(1):72-81. DOI:10.1002/bdd.690
34. Conte PF, Gennari A. Anthracyclines-paclitaxel combinations in the treatment of breast cancer. Ann Oncol. 1997;8(10):939-43. DOI:10.1023/a:1008208002779
35. Kamineni P, Prakasa K, Hasan SP, et al. Cardiotoxicities of paclitaxel in African Americans. J Natl Med Assoc. 2004;96(7):995.
36. Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991;9(9):1704-12. DOI:10.1200/JCO.1991.9.9.1704
37. Ghatalia P, Je Y, Kaymakcalan MD, et al. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer. 2015;112(2):296-305. DOI:10.1038/bjc.2014.564
38. National Cancer Institute DCTD Division of Cancer Treatment & Diagnosis. Common terminology criteria for adverse events (CTCAE). 2017. Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8..... Accessed 21.12.2021.
39. Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol. 2007;25(22):3362. DOI:10.1200/JCO.2006.09.6925
40. Martin P, Oliver S, Kennedy SJ, et al. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther. 2012;34(1):221-37. DOI:10.1016/j.clinthera.2011.11.011
41. Blackhall FH, O'brien M, Schmid P, et al. A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(8):1285-8. DOI:10.1097/JTO.0b013e3181e3a2d1
42. Liu Y, Liu Y, Fan ZW, et al. Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib. Eur J Clin Pharmacol. 2015;71(5):541-7. DOI:10.1007/s00228-015-1831-1
43. Anon. DailyMed – CAPRELSA – vandetanib tablet. National Library of Medicine. 2017. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e5721cb8-4185-47b9-bbb3-1c587e558a03&.... Accessed 21.12.2021.
44. Tolcher AW, Appleman LJ, Shapiro GI, et al. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2011;67(4):751-64. DOI:10.1007/s00280-010-1372-3
45. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204-12. DOI:10.1200/JCO.2007.15.6331
46. Bergh J, Mariani G, Cardoso F, et al. Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. Breast. 2012;21(4):507-13. DOI:10.1016/j.breast.2012.01.012
47. Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015;17(1):116-21. DOI:10.1093/neuonc/nou148
48. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841-51. DOI:10.1016/S1470-2045(11)70201-7
49. Larson RA, Yin OQ, Hochhaus A, et al. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2012;68(5):723-33. DOI:10.1007/s00228-011-1200-7
50. Abbas R, Chalon S, Leister C, et al. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol. 2013;71(1):123-32. DOI:10.1007/s00280-012-1987-7
51. Abbas R, Hug BA, Leister C, et al. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects. Int J Cancer. 2012;131(3):304-11. DOI:10.1002/ijc.27348
52. Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006;12(12):3762-73. DOI:10.1158/1078-0432.CCR-05-2095
53. Bates SE, Rosing DR, Fojo T, et al. Challenges of evaluating the cardiac effects of anticancer agents. Clin Cancer Res. 2006;12(13):3871-4. DOI:10.1158/1078-0432.CCR-06-1017
54. Lü S, Wang J, Xu X, et al. Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience. Int J Hematol. 2009;89(1):34-8. DOI:10.1007/s12185-008-0218-9
55. Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010;55(2):254-9. DOI:10.1002/pbc.22456
56. Maison-Blanche P, Vermorken JB, Goksel T, et al. A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel. J Cardiovasc Pharmacol. 2013;61(6):495-504. DOI:10.1097/FJC.0b013e31828b73ff
57. Ibrahim MA, Do DV, Sepah YJ, et al. Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate. BMC Pharmacol Toxicol. 2013;14:7. DOI:10.1186/2050-6511-14-7
58. Kloth JS, Pagani A, Verboom MC, et al. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer. 2015;112(6):1011-6. DOI:10.1038/bjc.2015.82
59. Coppola C, Rienzo A, Piscopo G, et al. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs. Cancer Treat Rev. 2018;63:135-43. DOI:10.1016/j.ctrv.2017.11.009
________________________________________________
2. Haddad PM, Anderson IM. Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death. Drugs. 2002;62(11):1649-71. DOI:10.2165/00003495-200262110-00006
3. Ventricular arrhythmias. Ventricular tachycardia and sudden cardiac death. Clinical recommendations of the Ministry of Health of the Russian Federation. 2020. Available at: https://mz19.ru/upload/iblock/dea/ZHeludochkovye-narusheniya-ritma.-ZHeludochkovye-takhikardii-2020..... Accessed 29.12.2021 (in Russian).
4. Golovina GA, Zafiraki VK, Kosmacheva EV. Drug-induced long QT syndrome. Vestnik aritmologii. 2020;27(3):42-52 (in Russian).
5. Aktürk G, Kalkan Ş. Drug-Induced QT Interval Prolongation: Mechanisms, Risk Factors, Genetics and Clinical Management. J Basic Clin Health Sci. 2019;3(5):193-8. DOI:10.30621/jbachs.2019.712
6. Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf. 2012;3(5):241-53. DOI:10.1177/2042098612454283
7. Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938-45. DOI:10.1016/j.jacc.2014.06.1167
8. Sarapa N, Huang M, Varterasian M, et al. Risk management and eligibility critieria for QT assessment in patients with advanced cancer. J Clin Oncol. 2005;23(16; Suppl.):3047.
9. Yusuf SW, Razeghi P, Yeh ETH. The Diagnosis and Management of Cardiovascular Disease in Cancer Patients. Curr Probl Cardiol. 2008;33(4):163-96. DOI:10.1016/j.cpcardiol.2008.01.002
10. Ostroumova OD, Goloborodova IV. The influence of certain groups of drugs on the QTc interval prolongation. Consilium Medicum. 2019;21(10):95-106 (in Russian). DOI:10.26442/20751753.2019.10.190447
11. Ostroumova OD, Goloborodova IV. Drug-induced prolongation of the QT interval: prevalence, risk factors, treatment and prevention. Consilium Medicum. 2019;21(5):62-7 (in Russian). DOI:10.26442/20751753.2019.5.190415
12. Woosley RL, Heise CW, Gallo T. CredibleMeds. Available at: https://crediblemeds.org/ Accessed: 29.12.2021.
13. Porta-Sánchez A, Gilbert C, Spears D, et al. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J Am Heart Assoc. 2017;6(12):007724. DOI:10.1161/JAHA.117.007724
14. Roden DM. A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. Cardiovasc Res. 2019;115(5):895-903. DOI:10.1093/cvr/cvz013
15. Cohen-Rabbie S, Berges AC, Rekić D, et al. QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small-Molecule New Drug Applications Approved During 2011–2019. J Clin Pharmacol. 2021;61(8):1106-17. DOI:10.1002/jcph.1844
16. Lazzerini PE, Bertolozzi I, Acampa M, et al. Androgen Deprivation Therapy for Prostatic Cancer in Patients With Torsades de Pointes. Front Pharmacol. 2020;11:684. DOI:10.3389/fphar.2020.00684
17. Abu Rmilah AA, Lin G, Begna KH, et al. Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. Int J Cancer. 2020;147(11):3160-7. DOI:10.1002/ijc.33119
18. Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol. 2018;36(3):231-7. DOI:10.1200/JCO.2017.74.7162
19. Larkin J, Del Vecchio M, Ascierto PA, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15(4):436-44. DOI:10.1016/S1470-2045(14)70051-8
20. Duan J, Tao J, Zhai M, et al. Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives. Oncotarget. 2018;9(39):25738-49. DOI:10.18632/oncotarget.25008
21. Dréno B, Ribas A, Larkin J, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol. 2017;28(5):1137-44. DOI:10.1093/annonc/mdx040
22. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689-99. DOI:10.1056/NEJMoa1411817
23. Schiefer M, Hendriks LEL, Dinh T, et al. Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring. Eur J Cancer. 2018;91:92-8. DOI:10.1016/j.ejca.2017.12.011
24. Hortobagyi GN. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Breast Cancer Res. 2018;20(1):123. DOI:10.1186/s13058-018-1050-7
25. Khozin S, Blumenthal GM, Zhang L, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res. 2015;21(11):2436-9. DOI:10.1158/1078-0432.CCR-14-3157
26. Wang H, Cao Q, Dudek AZ. Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res. 2012;32(3):1027-31.
27. Lenihan DJ, Kowey PR. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist. 2013;18:900-8.
DOI:10.1634/theoncologist.2012-0466
28. Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol. 2003;21:3609-15. DOI:10.1200/JCO.2003.10.009
29. Wacker A, Lersch C, Scherpinski U, et al. High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients. Oncology. 2003;65(2):108-12. DOI:10.1159/000072334
30. Koca D, Salman T, Unek IT, et al. Clinical and electrocardiography changes in patients treated with capecitabine. Chemotherapy. 2011;57(5):381-7. DOI:10.1159/000331645
31. Kuittinen T, Jantunen E, Vanninen E, et al. Late potentials and QT dispersion after high-dose chemotherapy in patients with non-Hodgkin lymphoma. Clin Physiol Funct Imaging. 2010;30(3):175-80. DOI:10.1111/j.1475-097X.2009.00920.x
32. Hancox JC, Caves RE, Choisy SC, et al. QT interval prolongation and torsades de pointes with oxaliplatin. Ther Adv Drug Saf. 2016;7(6):261-3. DOI:10.1177/2042098616666081
33. Yin W, Karyagina EV, Lundberg AS, et al. Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. Biopharm Drug Dispos. 2010;31(1):72-81. DOI:10.1002/bdd.690
34. Conte PF, Gennari A. Anthracyclines-paclitaxel combinations in the treatment of breast cancer. Ann Oncol. 1997;8(10):939-43. DOI:10.1023/a:1008208002779
35. Kamineni P, Prakasa K, Hasan SP, et al. Cardiotoxicities of paclitaxel in African Americans. J Natl Med Assoc. 2004;96(7):995.
36. Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991;9(9):1704-12. DOI:10.1200/JCO.1991.9.9.1704
37. Ghatalia P, Je Y, Kaymakcalan MD, et al. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer. 2015;112(2):296-305. DOI:10.1038/bjc.2014.564
38. National Cancer Institute DCTD Division of Cancer Treatment & Diagnosis. Common terminology criteria for adverse events (CTCAE). 2017. Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8..... Accessed 21.12.2021.
39. Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol. 2007;25(22):3362. DOI:10.1200/JCO.2006.09.6925
40. Martin P, Oliver S, Kennedy SJ, et al. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther. 2012;34(1):221-37. DOI:10.1016/j.clinthera.2011.11.011
41. Blackhall FH, O'brien M, Schmid P, et al. A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(8):1285-8. DOI:10.1097/JTO.0b013e3181e3a2d1
42. Liu Y, Liu Y, Fan ZW, et al. Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib. Eur J Clin Pharmacol. 2015;71(5):541-7. DOI:10.1007/s00228-015-1831-1
43. Anon. DailyMed – CAPRELSA – vandetanib tablet. National Library of Medicine. 2017. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e5721cb8-4185-47b9-bbb3-1c587e558a03&.... Accessed 21.12.2021.
44. Tolcher AW, Appleman LJ, Shapiro GI, et al. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2011;67(4):751-64. DOI:10.1007/s00280-010-1372-3
45. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204-12. DOI:10.1200/JCO.2007.15.6331
46. Bergh J, Mariani G, Cardoso F, et al. Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. Breast. 2012;21(4):507-13. DOI:10.1016/j.breast.2012.01.012
47. Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015;17(1):116-21. DOI:10.1093/neuonc/nou148
48. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841-51. DOI:10.1016/S1470-2045(11)70201-7
49. Larson RA, Yin OQ, Hochhaus A, et al. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2012;68(5):723-33. DOI:10.1007/s00228-011-1200-7
50. Abbas R, Chalon S, Leister C, et al. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol. 2013;71(1):123-32. DOI:10.1007/s00280-012-1987-7
51. Abbas R, Hug BA, Leister C, et al. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects. Int J Cancer. 2012;131(3):304-11. DOI:10.1002/ijc.27348
52. Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006;12(12):3762-73. DOI:10.1158/1078-0432.CCR-05-2095
53. Bates SE, Rosing DR, Fojo T, et al. Challenges of evaluating the cardiac effects of anticancer agents. Clin Cancer Res. 2006;12(13):3871-4. DOI:10.1158/1078-0432.CCR-06-1017
54. Lü S, Wang J, Xu X, et al. Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience. Int J Hematol. 2009;89(1):34-8. DOI:10.1007/s12185-008-0218-9
55. Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010;55(2):254-9. DOI:10.1002/pbc.22456
56. Maison-Blanche P, Vermorken JB, Goksel T, et al. A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel. J Cardiovasc Pharmacol. 2013;61(6):495-504. DOI:10.1097/FJC.0b013e31828b73ff
57. Ibrahim MA, Do DV, Sepah YJ, et al. Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate. BMC Pharmacol Toxicol. 2013;14:7. DOI:10.1186/2050-6511-14-7
58. Kloth JS, Pagani A, Verboom MC, et al. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer. 2015;112(6):1011-6. DOI:10.1038/bjc.2015.82
59. Coppola C, Rienzo A, Piscopo G, et al. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs. Cancer Treat Rev. 2018;63:135-43. DOI:10.1016/j.ctrv.2017.11.009
Авторы
О.Д. Остроумова*1,2, А.И. Кочетков1, В.А. Дё1
1 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия;
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*ostroumova.olga@mail.ru
1 Russian Medical Academy of Continuous Professional Education, Moscow, Russia;
2 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*ostroumova.olga@mail.ru
1 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия;
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*ostroumova.olga@mail.ru
________________________________________________
1 Russian Medical Academy of Continuous Professional Education, Moscow, Russia;
2 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*ostroumova.olga@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.